Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Gland Pharma Limited (NSE: GLAND), ISIN INE068V01023 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
GLAND last traded at ₹2908.00 (-0.31%), with a 52-week range of ₹1575.00 to ₹3041.95 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 51.77%, FIIs 8.74%, DIIs 30.44%, mutual funds 28.23%.
EquiSense Score (ECS): 78/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.